Categories
Credit Cards

Merrill Lynch Stick to Their Buy Rating for CVS Health Corp

Merrill Lynch analyst Michael Cherny maintained a Buy rating on CVS Health Corp (NYSE:CVS) on Tuesday, setting a price target of $83, which is roughly 9.11 % above the present share price of $76.07.

Cherny expects CVS Health Corp to publish earnings per share (EPS) of $0.93 for the earliest quarter of 2021.

The present consensus among 11 TipRanks analysts is for a reasonable Buy rating of shares in CVS Health, with an average price aim of $84.

The analysts priced targets range from a high of $101 to a low of $61.

In the newest earnings report of its, released on 09/30/2020, the company reported a quarterly revenue of $67.06 billion and a net gain of $3.25 billion. The company’s market cap is actually $99.57 billion.

Based on TipRanks.com, Merrill Lynch analyst Michael Cherny is presently ranked with four stars on a 0 5 stars ranking scale, with an average return of 11.5 % as well as a 60.53 % success rate.

CVS Health Corp. engages in the provision of health care services. It operates through the following segments: Pharmacy Services, retail or Long Term Care, Health Care Benefits, and Corporate. The Pharmacy Services segment extends pharmacy benefit management solutions. The retail or Long Term Care segment includes offering of prescription drugs and assortment of general merchandise.

The Health Care Benefits segment offers quite traditional, consumer-directed and voluntary health insurance products as well as related services, which includes medical, pharmacy, dental, behavioural health, healthcare control capabilities. The Corporate segment involves in providing management as well as administrative services. The company was created by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.

Leave a Reply

Your email address will not be published. Required fields are marked *